A practical reference on NAMPT: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-06 and is reviewed periodically as new material appears.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Terminology around NMN can be confusing because several related compounds share the vitamin B3 family. Nicotinamide riboside is a nucleoside, whereas NMN is a nucleotide with a phosphate group, and NAD+ is a dinucleotide coenzyme rather than a simple precursor. Niacin and nicotinamide are also NAD+ precursors but follow different metabolic entry points. In commercial and scientific writing, NMN usually refers to beta-nicotinamide mononucleotide unless another form is specified. Consistent nomenclature helps distinguish chemical identity from proposed biological effects.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a pyridine nucleotide that consists of a nicotinamide ring, a ribose sugar, and a phosphate group. It is an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+, synthesis. In mammalian cells, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. Nicotinamide mononucleotide adenylyltransferases then convert NMN into NAD+. The core structure and enzymatic route are well established in biochemical literature.
| Property | Value | Notes |
|---|---|---|
| Chemical name | Nicotinamide mononucleotide | Nucleotide intermediate in NAD+ salvage pathway |
| Common abbreviation | NMN | Also written as β-NMN |
| Molecular formula | C11H15N2O8P | Uncharged parent form |
| Molar mass | 334.22 g/mol | Calculated from formula |
| CAS Registry Number | 1094-61-7 | For β-nicotinamide mononucleotide |
In the salvage pathway, NMN is generated from nicotinamide and 5-phosphoribosyl-1-pyrophosphate by the enzyme nicotinamide phosphoribosyltransferase. A second route produces NMN from nicotinamide riboside through phosphorylation by nicotinamide riboside kinases. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferases, often called NMNAT enzymes. This stepwise route allows cells to recycle nicotinamide and maintain NAD+ levels under changing metabolic conditions. The relative contribution of each route varies by tissue, species, and physiological state, and it remains an active area of research.
Research on NMN has expanded because NAD+ concentrations decline with age in some tissues and because NAD+ participates in energy metabolism, DNA repair, and signaling. Animal studies have reported changes in NAD+ levels after NMN administration, but human data are more limited and often focus on safety, pharmacokinetics, and biomarker changes. Questions remain about oral absorption, tissue distribution, and whether changes in blood NAD+ reflect changes inside specific organs. NMN is not an approved drug, and claims about its clinical effects should be distinguished from established biochemical findings.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
In the canonical salvage pathway, nicotinamide phosphoribosyltransferase, known as NAMPT, transfers a phosphoribosyl group to nicotinamide and releases NMN. A second enzyme, NMN adenylyltransferase, then attaches an adenylyl group to NMN to form NAD+. Alternative routes exist, including a pathway that uses nicotinamide riboside and its phosphorylated forms. The relative contribution of extracellular NMN to intracellular NAD+ pools remains an area of active investigation, and the roles of specific transporters and enzymes are not completely defined.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in cells. Its structure consists of a nicotinamide ring linked to ribose phosphate, and the compound serves as an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+. In this pathway, nicotinamide phosphoribosyltransferase converts nicotinamide and phosphoribosyl pyrophosphate into NMN, after which NMN adenylyltransferase attaches an adenylate group to produce NAD+. Because NAD+ participates in redox reactions and signaling, NMN occupies a central position in cellular metabolism. The molecule is distinct from nicotinamide riboside, though the two are related in NAD+ precursor research.
Beyond its intracellular synthesis, NMN can be taken up from the extracellular environment, although the routes are still debated. Some evidence points to direct transport into cells through specific transporters, while other work suggests dephosphorylation to nicotinamide riboside followed by cellular uptake. Once inside, NMN can be converted to NAD+ by NMN adenylyltransferases; the relative contribution of these routes may differ by tissue, species, and experimental conditions. Researchers continue to investigate which mechanisms dominate in intact organisms and how they affect measured NAD+ levels. Direct measurement in tissues remains technically challenging because NMN can be rapidly metabolized during sample collection.
NMN occurs in many living systems, including bacteria, yeast, plants, and mammals. Dietary sources are present in foods such as edamame, avocado, broccoli, and various meats, but amounts vary widely and are generally lower than those used in research settings. Laboratory production often relies on enzymatic synthesis or chemical phosphorylation of nicotinamide riboside, and commercial material is typically supplied as a white to off-white powder. Because NMN is hygroscopic and sensitive to heat, moisture, and pH extremes, its handling requires care to preserve identity and purity. Aqueous preparation should be done with attention to pH and temperature to limit hydrolysis.
The SBP-Tag will also bind to streptavidin or streptavidin reagents in solution. Applications of these engineered associations include the visualization of specific proteins within living cells, monitoring of the kinetics of the translation of individual proteins in an in vitro translation system, control of the integration of a multi-spanning membrane protein into the endoplasmic reticulum by fusing the SBP-Tag to the N-terminal translocation sequence and then halting integration with streptavidin and restarting integration with biotin. Fluorescent streptavidin reagents (e.g. streptavidin-HRP) can be used to visualize the SBP-tag by immunoblotting of SDS-PAGE. Additionally, antibodies to the SBP-tag are available commercially. The SBP-Tag has been used to reversibly immobilize recombinant proteins onto streptavidin-functionalized surfaces thereby permitting interaction assessment such as by surface plasmon resonance (SPR) techniques with re-use of the functionalized surface. SPR has also been used to compare the SBP-Tag with other streptavidin-binding peptides such as Strep-tag.
One of the main roles of the INO80 subfamily is the incorporation and removal of alternate histones in the nucleosome. In the presence of the H2A.Z histone, the INO80 subfamily of remodelers catalyze the repositioning and eventual removal of this alternate histone. The H2A.Z histone is found on the first nucleosome at the beginning of genes. The INO80 subfamily of remodelers will also be recruited to the H2A.X histone in the homologous recombination repair pathway. In addition to this function, the INO80 subfamily plays a role in transcriptional regulation and genomic recombination. In the DNA damage pathways, the INO80 subfamily aids in repair, recombination, and cell cycle regulation. The INO80 subfamily can activate the recruitment of replication checkpoint factors and can aid in the recovery from replicative stress on the DNA strand. The subfamily's ability to incorporate alternate histones is important for genome stability, disease pathogenesis, and stem cell identity. INO80 complexes commonly bind to nucleosome free regions at transcription start sites and termination sites. INO80 is the only remodeler that is able to use the energy from ATP hydrolysis to create nucleosome free regions and cooperate with other remodelers to equally space nucleosomes.
Gastrointestinal side-effects (nausea, vomiting, diarrhoea) are common; the delayed-release formulation is meant to help overcome this problem. It is also a cause of drug-induced hepatitis. Patients with glucose-6-phosphate dehydrogenase deficiency should avoid taking aminosalicylic acid as it causes haemolysis. Thyroid goitre is also a side-effect because aminosalicylic acid inhibits the synthesis of thyroid hormones. Drug interactions include elevated phenytoin levels. When taken with rifampicin, the levels of rifampicin in the blood fall by about half. It is not known whether it will harm an unborn baby. With heat, 4-aminosalicylic acid is decarboxylated to produce CO2 and 3-aminophenol.
Firstly, the hydroxylation of compounds begins by cytochrome P450 enzymes. Secondly, hydrophilic moieties join up to the compounds in order to increase water solubility. As a result, the excretion through urine occurs and compounds can be removed. Either CYP4A or CYP4F are the enzymes involved in the downstream metabolism of 1-deoxySLs. It is not yet known which one takes place in the process but, it is more likely to be CYP4F as in mouse experiments this enzyme is responsible for 1-deoxySLs formation.
76. Hydromorphone. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2026 Sep 15. Limited data indicate that hydromorphone is excreted into breastmilk in small amounts, but large maternal dosages have caused neonatal central nervous system depression. In general, Maternal use of oral opioids during breastfeeding can cause infant drowsiness, which may progress to rare but severe central nervous system depression. Newborn infants seem to be particularly sensitive to the effects of even small dosages of narcotic analgesics. If hydromorphone is required by the mother of a newborn, it is not a reason to discontinue breastfeeding; however, once the mother’s milk comes in, it is best to provide pain control with a nonnarcotic analgesic and limit maternal intake of hydromorphone to 2 to 3 days at a low dosage with close infant monitoring.[1] If the baby shows signs of increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness, a physician should be contacted immediately. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breastfeeding is stopped.
Sources: en.wikipedia.org
=== Tissue regeneration === Collagen scaffolds are used in tissue regeneration, whether in sponges, thin sheets, gels, or fibers. Collagen has favorable properties for tissue regeneration, such as pore structure, permeability, hydrophilicity, and stability in vivo. Collagen scaffolds also support deposition of cells, such as osteoblasts and fibroblasts, and once inserted, facilitate growth to proceed normally.
Animal sinews and skins, including leather, have been used to make useful articles for millennia. Gelatin-resorcinol-formaldehyde glue (and with formaldehyde replaced by less-toxic pentanedial and ethanedial) has been used to repair experimental incisions in rabbit lungs.
The nucleophilic fluoride anion is basic, so anhydrous conditions are required to avoid competing reactions involving hydroxide, which is also a good nucleophile. The use of the cryptand to sequester the potassium ions avoids ion-pairing between free potassium and fluoride ions, rendering the fluoride anion more reactive. Intermediate 2 is treated with the protected mannose triflate (1); the fluoride anion displaces the triflate leaving group in an SN2 reaction, giving the protected fluorinated deoxyglucose (3). Base hydrolysis removes the acetyl protecting groups, giving the desired product (4) after removing the cryptand via ion-exchange:
== Research == In clinical trials of various design, 5-HTP has also been reported to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia. However, these clinical findings, as for all therapeutic findings with 5-HTP, are preliminary and need confirmation in larger trials.
Sources: en.wikipedia.org
=== Imaging === After determination using biomarkers, a variety of imaging studies may be used to differentiate between intrahepatic or extrahepatic cholestasis. Ultrasound is often used to identify the location of the obstruction but, is often insufficient in determining the level of biliary obstruction or its cause because it can pick up bowel gas that may interfere with readings. CT scans are not impacted by bowel gas and may also be more suitable for overweight patients. Typically, the cause of cholestasis and magnitude of obstruction is better diagnosed with CT compared to ultrasound. MRI scans provide similar information to CT scans but are more prone to interference from breathing or other bodily functions. Although CT, ultrasound, and MRI may help differentiate intrahepatic and extrahepatic cholestasis, the cause and extent of obstruction is best determined by cholangiography. Potential causes of extrahepatic cholestasis include obstructions outside the wall of the lumen, those outside the duct, and obstructions found in the duct lumen. Endoscopic retrograde cholangiography may be useful to visualize the extrahepatic biliary ducts. In case of anatomical anomalies, or if endoscopic retrograde cholangiography is unsuccessful, percutaneous transhepatic cholangiography may be used. CT or MRI-based cholangiography may also be useful, particularly in cases where additional interventions are not anticipated.
== Receptors == The studies cited above lead to the eventual cloning of the human Formyl peptide receptor 1, a G protein coupled receptor that binds fMLF and other formylated oligopeptides to mediate their stimulatory actions on human and rabbit neutrophils. Subsequently, Formyl peptide receptor 2 and Formyl peptide receptor 3 were also cloned based on the similarities in their amino acid sequence to that of formyl peptide receptor 1. Formyl peptide receptors 2 and 3 have very different abilities to bind and respond to formylated oligopeptides including fMLF compared to formyl peptide receptor 1 and compared to each other and have very different functions than those of formyl peptide receptor 1.
== Pseudo-Amino Acid Composition (PseAAC) model == The primary weakness of the discrete model that relies on the amino acid composition (AAC) is that the information on the frequencies of each amino acid from the sample alone involves a loss of sequence-order information, or information obtained by the order of the amino acid residues. To avoid this information loss, the concept of PseAAC (pseudo amino acid composition) was proposed. Under this new model, the first 20 discrete factors represent amino acid frequencies are retained, but additional discrete factors are included that also ascertain information about sequence order. The sequence order information is represented by what are called "pseudo components". The number of additional components, beyond the first 20 frequencies, is called λ (or upper-case Λ), and so 20+λ components are included in the model. The upper limit for λ is one less than the length of the shortest protein sample in the dataset. The total number of components (20+λ) may be denoted Ω. Any additional factors can be incorporated so long as they, in some way, obtain or represent information about the sequence-order. Typically, these are a series of rank-different correlation factors along the protein chain. The additional factors are a series of rank-different correlation factors along a protein chain, but they can also be any combinations of other factors so long as they can reflect some sorts of sequence-order effects one way or the other.
Sources: en.wikipedia.org
NMN is nicotinamide mononucleotide, a nucleotide intermediate in the NAD+ salvage pathway. Cells use it to help regenerate NAD+, a coenzyme involved in energy metabolism and cellular signaling. It is present naturally in many organisms and is also produced synthetically for research and consumer products.
NMN is the immediate precursor to NAD+ in the salvage pathway. The enzyme NMN adenylyltransferase adds an adenylate group to NMN to form NAD+. Because NAD+ levels decline with age in some tissues, researchers study whether raising NMN availability can influence NAD+ metabolism.
No. Human evidence is limited, and no regulatory agency has approved NMN for treating or preventing aging. Some trials measure NAD+ metabolites or metabolic markers, but their results do not establish a clinical benefit. Larger, longer studies with standardized endpoints are needed.
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide intermediate in NAD+ biosynthesis.